<DOC>
	<DOCNO>NCT00819585</DOCNO>
	<brief_summary>A 24-week , dose-ranging , multi-center , double-blind , double-dummy , active-controlled study evaluate canakinumab ( ACZ885 ) prophylaxis sign symptom acute flare chronic gout patient initiate allopurinol therapy</brief_summary>
	<brief_title>Evaluating Efficacy Canakinumab ( ACZ885 ) Prevention Acute Flares Chronic Gout Patients Initiating Allopurinol Therapy</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed write informed consent study procedure perform . History least 2 gout flare year prior Screening Visit ( base patient history ) , thus , candidate initiate uric acid lower therapy . Confirmed diagnosis gout meeting American College Rheumatology ( ACR ) 1977 preliminary criterion classification arthritis primary gout . Body Mass Index ( BMI ) ≤ 40 kg/m^2 . Willingness initiate allopurinol therapy urate lowering agent gout therapy initiate allopurinol therapy within ≤ 1 month Screening ( Visit 1 ) willing reinitiate allopurinol therapy stop &gt; 2 month Screening ( Visit 1 ) reason different toxicity/ intolerance lack efficacy . Acute gout flare within 2 week Screening ( Visit 1 ) Screening period History allergy contraindication colchicine allopurinol History intolerance allopurinol oral colchicine appropriate dose prophylactic use History bone marrow suppression Absolute relative contraindication naproxen oral prednisolone/ prednisone Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Gout</keyword>
	<keyword>Chronic Gout</keyword>
	<keyword>Gouty arthritis</keyword>
	<keyword>Gout flare</keyword>
</DOC>